Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant
Cai He, H. J. Yang, Weiqi Hong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment
Yujing Huang, Xiaohan Guo, Yi Wu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 109
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 44
Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies
Xun Wang, Shujun Jiang, Wentai Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 17
Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern
Swayam Prakash, Nisha R. Dhanushkodi, Latifa Zayou, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Wei Pang, Ying Lu, Yan‐Bo Zhao, et al.
Cell Research (2022) Vol. 32, Iss. 12, pp. 1068-1085
Open Access | Times Cited: 51
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
H. J. Yang, Weiqi Hong, Lei Hong, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 36
Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases
Yangzhuo Gu, H. J. Yang, Cai He, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 25
A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
Cai He, Aqu Alu, Lei Hong, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 21
Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants
Lei Hong, Aqu Alu, H. J. Yang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
A Smart DNA‐Based Nanosystem Containing Ribosome‐Regulating siRNA for Enhanced mRNA Transfection
Zhaoyue Lv, Mengxue Huang, Jing Yang, et al.
Advanced Materials (2023) Vol. 35, Iss. 36
Open Access | Times Cited: 18
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
Xuemei He, Cai He, Weiqi Hong, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 4, pp. 932-971
Open Access | Times Cited: 17
Combining Phage Display Technology with In Silico -Designed Epitope Vaccine to Elicit Robust Antibody Responses against Emerging Pathogen Tilapia Lake Virus
Yu‐Ming Gong, Xuefeng Wei, Yuying Zheng, et al.
Journal of Virology (2023) Vol. 97, Iss. 4
Open Access | Times Cited: 15
The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2
Yuan Hu, Lili Liu, Shenghua Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 5, pp. 5175-5192
Open Access | Times Cited: 6
Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies
Xun Wang, Shujun Jiang, Wentai Ma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseases
Yang Zeng, Olivia J. Young, Longlong Si, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Alterations in microbiota of patients with COVID‐19: implications for therapeutic interventions
Yong Qiu, Chunheng Mo, Lu Chen, et al.
MedComm (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 5
Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines
Zhaoling Shen, Cheng Li, Wenping Song, et al.
PLoS Pathogens (2025) Vol. 21, Iss. 1, pp. e1012845-e1012845
Open Access
Chemical cross‐linking facilitates antigen uptake and presentation and provides improved protection from Mpox with a dual‐antigen subunit vaccine
Long Chen, Chao Shang, Zihao Wang, et al.
MedComm (2025) Vol. 6, Iss. 1
Open Access
Recombinant probiotic Escherichia coli delivers the polymeric protein of swine influenza virus for protection
Jinmei Sun, Wenqiang Zhang, Yanjin Li, et al.
Veterinary Microbiology (2025) Vol. 302, pp. 110401-110401
Closed Access
A Universal Therapeutic Vaccine Leveraging Autologous Pre‐Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells
Fuhua Wu, Zhaofei Guo, Jialiang Yang, et al.
Advanced Materials (2025)
Closed Access
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants
H. J. Yang, Weiqi Hong, Shi H, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development
Janet K. Yamamoto, Lekshmi K. Edison, Dawne K. Rowe-Haas, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 914-914
Open Access | Times Cited: 12
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
Science Advances (2023) Vol. 9, Iss. 23
Open Access | Times Cited: 12
Dynamic Profiling and Prediction of Antibody Response to SARS-CoV-2 Booster-Inactivated Vaccines by Microsample-Driven Biosensor and Machine Learning
Sumin Bian, Min Shang, Ying Tao, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 352-352
Open Access | Times Cited: 4
Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
Yulei Li, Peipei Liu, Tianjiao Hao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top